文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

哥伦比亚全国代表性调查:二代测序揭示HIV治疗前耐药现状

National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究对2021至2023年哥伦比亚全国代表性样本进行横断面调查,采用二代测序分析483例首次或重新开始一线抗逆转录病毒治疗者的治疗前耐药。总体耐药率为20.3%,以非核苷类逆转录酶抑制剂耐药为主(18.0%),整合酶抑制剂耐药罕见(2.1%)。

要点

  • 哥伦比亚治疗前HIV耐药率高达20.3%,主要由NNRTI耐药驱动。
  • K103N是最常见的耐药突变,INSTI耐药突变仅占2.1%。
  • 建议淘汰依非韦伦方案,推广二代INSTI为基础的一线治疗。

核心结论

  • 哥伦比亚治疗前NNRTI耐药率高得惊人,而INSTI耐药率极低,亟需淘汰依非韦伦方案。

研究设计与样本

  • 横断面全国代表性调查,采用二代测序分析2021至2023年483例首次或重新开始一线抗逆转录病毒治疗者的血浆样本。

主要发现

  • 总体治疗前耐药率为20.3%(95%CI 16.8-24.2),NNRTI耐药率为18.0%(95%CI 14.7-21.7),K103N为最常见耐药突变。
  • INSTI耐药突变罕见,占2.1%;野生型病毒占61.7%。
  • 98.3%为HIV-1 B亚型,94.3%为哥伦比亚籍,中位年龄32.5岁(标准差±10.8),女性占19.9%,CD4<200 cells/mm³者占27.5%。
  • 中位HIV-1 RNA为54 754 copies/mL(IQR:15 685-166 000),6.2%为重新开始治疗者。

关键数值与推荐

  • 耐药突变按世界卫生组织建议分析,并使用Stanford HIVdb v9.6解读。

临床怎么用

  • 应加速淘汰基于依非韦伦的一线方案,推广可负担的二代INSTI为基础的治疗。
  • 加强处方者教育以维持疗效并防止耐药毒株传播。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV pretreatment drug resistance (PDR) is an increasing global concern affecting transmitted resistance and first-line therapy effectiveness. Colombia lacks recent nationwide data on transmitted resistance. Although national guidelines recommend second-generation integrase strand transfer inhibitors (INSTIs) as preferred first-line options, efavirenz remains widely prescribed. This study estimated HIV PDR prevalence in Colombia to inform best practices for first-line antiretroviral therapy. METHODS: We conducted a cross-sectional, nationally representative survey using next-generation sequencing of plasma samples from individuals initiating or reinitiating first-line antiretroviral treatment across Colombia's natural regions, stratified by national HIV prevalence data. Samples collected between 2021 and 2023 were analysed for drug resistance mutations (DRMs) following World Health Organization recommendations and interpreted using Stanford HIVdb v9.6. RESULTS: A total of 483 participants were enrolled; 98.3% had HIV-1 subtype B, 94.3% were Colombian nationals, the median age was 32.5 years (standard deviation ± 10.8), 19.9% were female, and 27.5% had CD4 counts <200 cells/mm³. Median HIV-1 RNA was 54 754 copies/mL (interquartile range [IQR]: 15 685-166 000); 6.2% were treatment reinitiators. The wild-type virus was identified in 61.7%. Overall, PDR prevalence was 20.3% (95% confidence interval [CI] 16.8-24.2), driven mainly by non-nucleoside reverse transcriptase inhibitor resistance (NNRTI) (18.0%, 95% CI 14.7-21.7), with K103N as the most frequent DRM. INSTI DRMs were rare (2.1%). CONCLUSIONS: This nationwide survey demonstrates alarmingly high NNRTI resistance but minimal INSTI resistance, underscoring the urgent need to phase out efavirenz-based regimens. Strengthening access to affordable second-generation-based therapies and enhancing prescriber education are critical to sustaining treatment efficacy and preventing further transmission of resistant HIV strains.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Martínez-Buitrago E, Zapata-Marín AF, Rubiano LC, et al. National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing. J Antimicrob Chemother. 2026. PMID: 41424101. doi:10.1093/jac/dkaf444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。